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Opening options for material transfer
Linda Kahl, Jennifer Molloy, Nicola Patron, Colette Matthewman, Jim Haseloff, David Grewal, Richard Johnson & Drew Endy
The Open Material Transfer Agreement is a material-transfer agreement that enables broader sharing and use of biological 
materials by biotechnology practitioners working within the practical realities of technology transfer.
Material-transfer agreements (MTAs) underlie the legal frameworks within 
which biotechnology practitioners define the 
terms and conditions for sharing biomateri-
als ranging, for example, from plasmid DNA 
to patient samples. If MTAs are easy to use 
and well adapted to the needs of individual 
researchers, institutions, and broader com-
munities, then more sharing, innovation, 
and translation can occur. However, the MTA 
frameworks currently in place were developed 
in the 1990s—before widespread adoption 
of the World Wide Web, genome sequenc-
ing, and gene synthesis—and are not always 
well adapted for contemporary research and 
translation practices or aligned with social 
objectives.
Here, we introduce a new MTA, the Open 
Material Transfer Agreement (OpenMTA), 
that relaxes restrictions on the redistribu-
tion and commercial use of biomateri-
als while maintaining aspects of standard 
MTAs that support widespread adoption (for 
example, incorporation into semiautomated 
administration systems). In developing the 
OpenMTA, our motivation was to realize a 
simple, standardized legal tool for sharing 
biological materials as broadly as possible 
without undue restrictions, while respecting 
the rights of creators and promoting safe prac-
tices and responsible research. Importantly, 
we wanted the tool to work within the practi-
cal realities of technology transfer and to be 
sufficiently flexible to accommodate the needs 
of many groups globally (for example, pro-
viding support for international transfers and 
compatibility with public and philanthropic 
funding policies).
Traditional MTAs
Currently, the most used MTA in biol-
ogy and biotechnology is the Uniform 
Biological Material Transfer Agreement 
(UBMTA), which was developed and widely 
adopted in the 1990s (https://www.ott.nih.
gov/resources/). The UBMTA represented 
a major step forward in providing a stan-
dard template intended to help decrease 
administrative transaction costs for material 
exchange among academic research institu-
tions. Despite widespread adoption of the 
UBMTA, many institutions continue to insist 
on MTAs specific to their own institution1. In 
many cases, the effort required to implement 
MTAs has increased, because the complexity 
of included provisions requires protracted 
negotiation. Such transaction costs not only 
impede the distribution of materials within 
and beyond research communities but also 
place an unnecessary burden on technology 
transfer offices, thus leading some institu-
tions to adopt a ‘no MTA’ policy2,3. Although 
eliminating the explicit execution of MTAs 
decreases the apparent administrative bur-
den, the resulting reality is less than ideal, 
because MTAs also help with provenance 
tracking, recognition, and quality control. In 
addition, because some no-MTA policies state 
that transfers made without an explicit agree-
ment default to the terms of the UBMTA, 
and because researchers may share materials 
informally without knowing that such terms 
apply by default4, the ability of everyone to 
legitimately use and further develop materials 
remains in limbo, at best.
Most widely used MTAs place two restric-
tions on material transfers, neither of which is 
often useful or desired (Table 1). First, MTAs 
typically disallow redistribution of materials 
(i.e., so-received materials cannot formally be 
shared with others). Second, any and all com-
mercial uses of the so-received biomaterials 
are specifically prohibited. Although these 
two restrictions are appropriate for materials 
that require tight control of provenance for 
reasons of safety, security, or commercializa-
tion, such restrictions make little sense for 
most of the materials used widely throughout 
research (for example, basic samples, strains, 
or plasmids). Because the potential com-
mercial value of most widely used materials 
is quite low, and MTAs are unlikely to ever 
be monitored and enforced1, blanket restric-
tions on redistribution and commercial use 
create unnecessary barriers and costs within 
research communities and to society at large.
For example, with the ongoing emergence 
of a second generation of biotechnology 
practitioners who are increasingly empow-
ered by information-sharing networks and 
DNA sequencing and synthesis capacities—
which together make genetic information 
and material interconvertible—both the 
‘no redistribution’ and ‘no commercial use’ 
restrictions can be quite harmful. As one 
example, over the past 15 years, the interna-
tional genetically engineered machines com-
petition (http://igem.org/) has developed 
into a genetic engineering ‘olympics’ involv-
ing ~6,000 students per year, in which stu-
dents freely share biological materials under 
a get-and-give policy. Many of these students, 
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having just prototyped a compelling biotech-
nology application, then wish to start a com-
pany to translate their innovation. Yet, the 
materials that they themselves developed via 
an open and collaborative community cannot 
be directly used in their subsequent commer-
cial activities.
As a second specific example, Addgene 
has become a major public-benefit plas-
mid-sharing resource; it has shipped more 
than 950,000 plasmids to over 6,400 institu-
tions in 93 countries since starting in 2004. 
Technology-transfer offices are enormously 
appreciative of the services that Addgene 
provides, which include electronic processing 
of MTAs. Yet, because the UBMTA was the 
default standard at the time Addgene’s elec-
tronic MTA system was developed, commer-
cial biotechnology researchers are unable to 
directly access most of the resources available 
via Addgene. This MTA-induced limitation 
arises even though many of the Addgene-
hosted materials are not subject to any specific 
proprietary interest. Although well-funded 
commercial groups can gain access to such 
materials via ab initio DNA synthesis starting 
from sequences available on Addgene’s web-
site or other public databases, the companies 
that might benefit the most from such mate-
rials—the small start-up or midsized com-
panies representing the lifeblood and future 
of biotechnology—are left out. Defaulting to 
restrictive terms that may not be uniformly 
necessary or appropriate is common with 
other repositories, including nonprofit culture 
collections, biobanks, gene banks, seed banks, 
and other plasmid repositories that have been 
established in recognition of their importance 
to various biotechnology communities.
Making research tools broadly available 
for use without restriction can accelerate the 
pace of research, improve the reproducibility 
of results, and save the time and costs that 
would otherwise be incurred by researchers 
recreating tools and materials in their own lab-
oratories. Today, researchers in many branches 
of biotechnology including synthetic biology, 
genomics, and regenerative medicine are cre-
ating nucleic acid–based tools as well as other 
tools intended for widespread use and contri-
bution to the public domain. Examples include 
molecular probes for drug discovery from the 
Structural Genomics Consortium, pluripo-
tent stem cell lines from Boston University’s 
Center for Regenerative Medicine, materials 
from the Montreal Neurological Institute and 
Hospital, functional genetic elements from the 
BIOFAB project, DNA part collections from 
OpenPlant, and the bionet.io and Free Genes 
projects from the BioBricks Foundation5–10. 
The desire of these researchers and organiza-
tions to share materials freely is rooted in the 
idea that, although there may be limited value 
in each of these tools individually, there is great 
value in their widespread use by researchers 
and others collectively. This idea is particularly 
relevant to synthetic biology, in which stan-
dards have been developed for the interoper-
ability of modular DNA components or parts, 
and in which remixing of numerous parts is 
normal practice11,12. Nonetheless, accessing 
materials remains difficult and time consum-
ing or impossible, thus leading to delays or lost 
opportunities.
Drafting the OpenMTA
The OpenMTA was developed as a collab-
orative effort led by the BioBricks Foundation 
and the OpenPlant Synthetic Biology Research 
Centre. We began by convening a working 
group comprising researchers, technology-
transfer professionals, social scientists, legal 
experts, and others interested in creating a 
legal framework that could improve shar-
ing of biomaterials. This group, which met 
in person in June  2015 and continued with 
scheduled online meetings, developed the 
design goals for the OpenMTA, including 
access, attribution, reuse, redistribution, and 
nondiscrimination (Fig. 1). These five design 
goals were selected to be consistent with the 
Open Definition, which aims to “make pre-
cise the meaning of ‘open’ with respect to 
knowledge, promoting a robust commons in 
which anyone may participate, and interop-
erability is maximized” (https://opendefini-
tion.org/). Additional design goals included 
issues of safety and, in particular, the sharing 
of biomaterials in an international context. 
For example, we wanted the agreement to be 
usable by institutions worldwide (i.e., to not 
be US- or UK-centric). After the design goals 
were in place, we drafted the legal text for the 
OpenMTA.
We used the text of the UBMTA as a start-
ing point, removing any aspects that did not 
meet the design goals, and adding or refin-
ing text to strengthen aspects as needed. The 
resulting OpenMTA drafts went through 
several rounds of revision, beginning with 
review by the offices responsible for trans-
fer of materials from OpenPlant, includ-
ing Cambridge University, Cambridge 
Enterprise, and the John Innes Centre. 
Additional input was solicited by e-mail 
and by contacting the members of Praxis 
Unico and the Association for University 
Technology Managers. Revisions continued 
until the received comments reflected no new 
issues, at which point the OpenMTA text was 
officially posted online with digital-signature 
capability (http://openmta.org).
The OpenMTA has many features in com-
mon with other standard MTA templates, 
such as provisions on use, compliance, and 
liability, that help protect the provider and 
clarify the responsibility of the recipient 
(Table 1). Like all MTAs, the OpenMTA is 
a contract—a bargained-for exchange of 
Table 1  Comparison of features and terms for standard MTAsa
Features and terms of transfer UBMTA 
(1995)
SLA 
(1999)
Science 
Commons 
(2005–2009)
OpenMTA 
(2018)
Similarities
Use for research and teaching Yes Yes Yes Yes
Attribution Yes Yes Yes Yes
Compliance with laws and regulations Yes Yes Yes Yes
No warranty (for example, third-party rights) Yes Yes Yes Yes
Recipient assumes liability Yes Yes Yes Yes
Recipient indemnifies provider No No No No
Reach-through rights or restrictions No No No No
Fees for preparation and distribution 
(optional)
Yes Yes Yes Yes
Fees for royalties No No No No
Provenance tracking Yes Yes Yes Yes
Alignment with policies of public and private 
funders of research
Yes Yes Yes Yes
Differences
Academia or nonprofit only Yes No No No
Ease of use internationally No Yes Yes Yes
Distribution of materials or derivatives No No No Yes
Use for commercial purposes No No No Yes
aUBMTA, Uniform Biological Material Transfer Agreement (https://www.ott.nih.gov/resources/); SLA, NIH Simple Letter 
Agreement (https://www.ott.nih.gov/resources/); Science Commons MTA19.
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consideration—wherein materials from the 
provider are given in exchange for a promise 
by the recipient to abide by the terms of the 
agreement, including attribution, reporting 
back, and payment of a fee for processing 
if requested. Although litigation of MTAs 
is exceedingly rare, a framework based on 
providing material in exchange for a prom-
ise meets the legal standards for adequate 
consideration1. As part of the promise, the 
OpenMTA includes a provision that requires 
recipients of the materials to “ensure com-
pliance with all applicable laws, rules, and 
regulations.” This provision was included 
to provide flexibility and stability in use of 
the OpenMTA because, as is the case for all 
MTAs, the transfer of specific materials may 
be subject to laws, rules, and regulations that 
are context dependent, jurisdictional, and 
subject to change over time (for example, 
access and benefit-sharing obligations aris-
ing from the Convention for Biodiversity and 
Nagoya Protocol (https://www.cbd.int/abs/)). 
The OpenMTA also includes an optional 
‘catch-all’ term specifying “information rel-
evant to the status of the Material is provided 
in an attachment.” This optional term, sug-
gested during the iterative review process 
as a means to capture unique or unforeseen 
circumstances, could be used to notify the 
recipient of any additional obligations that 
might apply to use of the material (for exam-
ple, uses specified in patent claims). Finally, 
because the OpenMTA includes the same ‘no 
warranty’ provision as that provided in the 
UBMTA and other standard agreements, the 
recipients remain responsible for conducting 
their own due diligence for their use of the 
materials in their jurisdiction.
Differences between the OpenMTA and 
other standard templates arise via differ-
ences in design—specifically that researchers 
be allowed to use the materials for any law-
ful purpose, including commercial purposes, 
and may also redistribute the materials to oth-
ers, subject to reporting back if requested by 
the providing institution. Reporting back was 
included as an optional term because technol-
ogy transfer offices expressed different prefer-
ences. Some wanted reporting back as a means 
to measure the influence of research materials 
made freely available to others, whereas others 
did not want to track the materials beyond the 
first transfer.
Although the OpenMTA can be used as 
an integrated agreement, the online ver-
sion of the OpenMTA is structured as a 
Master Agreement that can be approved 
at an institutional level. The online Master 
Agreement ensures consistency in the use 
of the OpenMTA (i.e., no altering of terms 
or editing), and also provides transparency 
for the individuals and institutions that have 
become signatories (i.e., signatories can be 
listed online for easy reference). After an insti-
tution becomes a signatory to the OpenMTA 
Master Agreement, transfers can be made 
with the use of an implementing letter. Doing 
so simplifies the material-transfer process by 
eliminating the need for review of terms and 
provides the documentation necessary for 
provenance tracking.
Importantly, we note that becoming a sig-
natory to the OpenMTA Master Agreement 
provides an institution and its researchers 
the option of transferring materials under the 
terms of the OpenMTA but does not obligate 
its exclusive use. Institutions retain full discre-
tion to handle the transfer of specific materials 
on a customized basis. Institutions also retain 
the discretion to designate authorized signato-
ries for the implementing letter. In other words, 
use of the OpenMTA is not mandatory, even 
for signatory institutions, and institutional 
signatory authority is still required unless the 
institution decides otherwise. Additionally, 
because the OpenMTA does not include a 
‘viral’ clause, institutions may accept incoming 
materials under the OpenMTA, use or modify 
so-received materials, and then subsequently 
redistribute the materials or derivatives under 
the same or different terms. This additional 
flexibility supports broad use of materials made 
available under the OpenMTA, even in cases in 
which more restrictive terms are best suited for 
redistribution.
As a standard template, the OpenMTA 
lends itself to automation that can further 
accelerate and simplify MTA processing 
while providing a less restrictive option for 
material transfer as appropriate. Within cen-
tralized repositories such as Addgene, for 
example, the OpenMTA should be able to 
be incorporated as an option alongside the 
UBMTA so that researchers and institutions 
can easily select the terms best suited for their 
needs. Additionally, the provenance-tracking 
capability inherent in Addgene’s electronic 
MTA system13,14, with the necessary permis-
sions, could provide increased transparency 
in the dissemination of research tools and 
help inform science policy. Stated differently, 
institutions may choose to use a centralized 
repository to distribute materials under the 
OpenMTA to be readily recognized for reach-
ing the widest possible audience and enabling 
the greatest social good.
Incorporation of the OpenMTA within other 
electronic platforms, such as the MTAShare 
platform developed at Vanderbilt University 
(https://cttc.co/inventors/mtashare/) and 
the Transfer Agreement Dashboard hosted 
by the US National Institutes of Health15, 
could also enable less restrictive options for 
sharing biomaterials as appropriate. These 
platforms are designed for direct transfer of 
materials from one institution to another and 
provide an avenue for researcher-led sharing 
of materials. Although researcher-led shar-
ing of materials may lack the quality control 
of centralized repositories, such an approach 
Access
Attribution
ReuseRedistribution
Nondiscrimination
Material transfer is supported
 between researchers at all 
institutions, including academic, 
industrial, government and 
community laboratories
No party is restricted from
selling or giving away the materials,
either as received or as part of a
collection or derivative work
Materials may be modified or 
used to create new substances
Providers may request 
acknowledgement of the 
source of materials 
in publications
Access is free of any royalties 
or fees, other than appropriate 
and nominal fees for preparation 
and distribution
Figure 1  Design goals for the OpenMTA. The design goals for the OpenMTA reflect the principles of 
‘openness’ set out in the Open Definition (https://opendefinition.org/). These design goals, together with 
additional goals to ensure safety and enable sharing of biomaterials in an international context, were 
used to help guide the drafting of the legal text for the OpenMTA.
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is practically essential for materials undergo-
ing rapid iterative changes or to support broad 
collaborations and rapid scaling. Technology-
transfer offices could still review and approve 
such transfers, and paperwork and individual 
negotiations could be replaced by electric 
communications and selection from a set of 
standard MTA templates. Such electronic plat-
forms could also offer provenance tracking, so 
that researchers and their institutions would 
be better able to make informed choices about 
the materials they use in their research.
Use of the OpenMTA
We anticipate that the OpenMTA will be most 
useful for the transfer of biomaterials used in 
precompetitive research, such as plasmids, 
strains, and samples, whose quantities are not 
limited, owing to the easily replicated nature 
of the materials, and for which the value of 
individual materials is relatively low, owing 
to alternative sourcing options. We further 
anticipate that the OpenMTA may be well 
suited as a default institutional policy in con-
texts in which most materials are intended to 
be freely shared. We note that the OpenMTA is 
not suitable for all transfers, such as materials 
that are in limited quantity or subject to strict 
biosecurity regulations.
The OpenMTA does allow for recovery of 
costs associated with preparation and distri-
bution of materials and therefore could also 
be used for the transfer of research reagents 
such as antibodies, cell lines, and fluorescent 
proteins for which patents have expired or 
were never sought. Indeed, the introduction 
of OpenMTA for sharing biological materials 
is particularly timely in that many patented 
materials are now entering the public domain 
as patents expire. As one example, a collec-
tion of patents on green fluorescent proteins 
initially aggregated and outlicensed by GE 
Healthcare Lifesciences16 have all expired 
(Table 2). Moreover, patent claims to nucleic 
acid sequences are now subject to heightened 
scrutiny and, if issued at all, are drawn much 
more narrowly than in the past17,18.
We have received numerous inquiries about 
the suitability of the OpenMTA for the trans-
fer of human-derived materials. Additional 
complexities including privacy, consent, and 
institutional-review-board approval must be 
addressed, and we are working with others 
to develop an OpenMTA for such materi-
als. Extending these efforts to enable more 
open sharing of induced pluripotent stem 
cell lines, for example, in coordination with 
national and international registries, could 
vastly accelerate the development of useful 
biomedical applications.
Practically, the OpenMTA is already being 
used via the BioBricks Foundation’s Free 
Genes project, wherein sequences requested 
by the synthetic biology research community 
are synthesized and made available with-
out cost. The OpenPlant Synthetic Biology 
Research Centre plans to use the OpenMTA 
to distribute vectors that incorporate a com-
mon syntax with wide acceptance in the area 
of plant biotechnology. The online OpenMTA 
Master Agreement is already gaining trac-
tion, and it includes initial signatories from 
academic research institutions, companies, 
and community labs. We invite more sig-
natories and welcome public comments on 
the OpenMTA Master Agreement, which 
is freely available via http://openmta.org 
and as Supplementary  Data. Comments 
may be addressed to The OpenMTA 
Project, BioBricks Foundation, 77  Van 
Ness Avenue, Ste. 101-1626, San Francisco, 
California, 94102, USA, or sent by email to 
openmta@biobricks.org or to either corre-
sponding author.
Note: Any Supplementary Information and Source Data 
files are available in the online version of the paper.
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